fbpx Announcing the BLUE KNIGHT™ QuickFire Challenge: Next-Generation Preparedness Solutions - News | JLABS

Announcing the BLUE KNIGHT™ QuickFire Challenge: Next-Generation Preparedness Solutions

May 4, 2022 -
13 days ago
Other news

May 4, 2022  Johnson & Johnson Innovation, together with BARDA, are proud to launch the BLUE KNIGHT™ QuickFire Challenge: Next-Generation Preparedness Solutions. Innovators are invited to submit potentially ground-breaking ideas or technologies that aim to enhance preparedness towards future known and unknown infectious disease threats.

In today’s interconnected world, there is a greater need to work together to spark potential solutions for tomorrow’s known and unknown public health threats. New innovations, particularly those with multi-use potential, are needed to help rapidly and efficiently respond to emerging health security threats and infectious diseases.

BLUE KNIGHT™a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), seeks to answer this call by anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements.

Up to four innovator(s) with the best potential solution can receive award funding from a total pool of up to $200,000 and access to the global Johnson & Johnson Innovation – JLABS network through Blue Knight residency with mentorship from experts at the Johnson & Johnson Family of Companies and BARDA.*

Apply at jji.jnj/blue-knight-quickfire by July 22, 2022.

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to help address today’s greatest health care challenges.

Want to learn more about Blue Knight? Join us on June 9, 2022 for the BLUE KNIGHT™ Symposium 2022: The Power of Partnering to Accelerate Preparedness to dive into a global conversation on advancing next-gen potential preparedness solutions. Register here: https://jji.jnj/bksymposium.

* Subject to the execution of the necessary documentation and (award) agreements.  

About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.

About HHS, ASPR, and BARDA:

HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to save lives and protect Americans from 21st century health security threats. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products – needed to combat health security threats. To date, BARDA-supported products have achieved over 60 FDA approvals, licensures or clearances. To learn more about BARDA’s portfolio and about partnering with BARDA, visit www.medicalcountermeasures.gov/.

About BLUE KNIGHT™

Blue Knight is a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. This collaboration aims to stimulate the innovation and incubation of science and technologies that may improve health security and response by supporting companies focused on public health threats and emerging infectious diseases. Find out more about BARDA and its mission at www.medicalcountermeasures.gov/.


Related content